MetaCap

Beam Therapeutics (BEAM) vs Vericel (VCEL)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Vericel (VCEL) has outperformed Beam Therapeutics (BEAM) over the past year, gaining 45.3% versus a loss of 5.9%. Over five years, VCEL leads with a +50.1% price change compared with -73.4% for BEAM. Vericel is the larger company by market cap ($2.94 billion vs $2.16 billion), about 1.4 times the size, while Beam Therapeutics is growing revenue faster (+120.0% vs +16.5%).

Vericel converts more of its revenue into profit, with a net margin of 6.0% versus -57.2%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BEAM-5.90%VCEL+45.33%
+76%+22%-31%
Nov 21, 20251 yearNov 20, 2026
BEAM-76.70%VCEL+29.75%
+40%-24%-89%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BEAM versus VCEL key metrics
MetricBEAMVCEL
Share price$20.90$57.52
Market cap$2.16B$2.94B
1-day change-0.19%-1.27%
YTD return-24.60%+59.73%
1-year return-5.90%+45.33%
5-year return-73.44%+50.14%
P/E ratio (TTM)—89.88
Forward P/E—61.06
EPS (TTM)$-0.87$0.64
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$139.74M$276.26M
Revenue growth (YoY)+120.01%+16.45%
Net income (latest FY)$-79.99M$16.52M
Gross margin—74.42%
Operating margin-274.57%4.00%
Net margin-57.24%5.98%
52-week high$38.26$59.75
52-week low$20.44$28.95
Distance from 52-week high-45.37%-3.73%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+138.52%+13.75%
Average volume2.04M664.34K
Shares outstanding103.50M51.03M
Employees557398
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • VCEL has outperformed BEAM by 51.2 percentage points over the past year.
  • Vericel is more profitable, keeping 6.0 cents of every revenue dollar as net income versus -57.2 cents for Beam Therapeutics.
  • Beam Therapeutics grew revenue faster in its latest fiscal year (+120.01% vs +16.45%).

About Beam Therapeutics

BEAM stock →

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 557 employees

About Vericel

VCEL stock →

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 398 employees

BEAM vs VCEL FAQ

Which is bigger, Beam Therapeutics or Vericel?

Vericel (VCEL) is larger, with a market capitalization of $2.94B compared with $2.16B for Beam Therapeutics (BEAM).

Which stock has performed better over the past year, BEAM or VCEL?

VCEL returned +45.33% over the past 12 months, compared with -5.90% for BEAM (price return, excluding dividends). Past performance does not predict future results.

Are Beam Therapeutics and Vericel in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons